Page last updated: 2024-12-07

trisequens

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trisequens: triphasic preparation for estrogen replacement therapy; each 28-day calendar pack contains 12 tablets of estradiol 2 mg & estriol 1 mg, 10 of estradiol 2 mg & estriol 1 mg & norethisterone acetate 1 mg, 6 of estradiol 1 mg & estriol 0.5 mg [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123634
MeSH IDM0100249

Synonyms (7)

Synonym
trisekvens
66100-41-2
[(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17
trisequens forte
kliojest
trisequens
19-norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17alpha)-, mixt. with (17beta)-estra-1,3,5(10)-triene-3,17-diol and (16alpha,17beta)-estra-1,3,5(10)-triene-3,16,17-triol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The incidences of adverse events were similar in all groups."( Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser, T; Koytchev, R; Müller, A; Oettel, M, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile of the serum concentrations of estradiol was measured on day 1, 21 and 28 each immediately before and 1, 2, 4, 6, 8, and 10 hours after intake of a tablet, and the AUC (area under the curve) was calculated."( [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
Fink, T; Kuhl, H; Lang, E; Leukel, P; Rohr, UD; Wiegratz, I, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
"The dose-response effects on serum lipids and lipoproteins were studied in 87 healthy post-menopausal women treated for 1 yr with three different doses of sequential oestrogen/progestogen (4 mg, 2 mg and 1 mg 17 beta-oestradiol cyclically combined with 1 mg norethisterone acetate) or placebo."( Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in post-menopausal women.
Christiansen, C; Jensen, J, 1987
)
0.27
" The results showed reduced levels of both estrogens in smokers as compared with nonsmokers in all three dosage groups."( Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause.
Christiansen, C; Jensen, J; Rødbro, P, 1985
)
0.27
" They received continuously 17 beta estradiol in dosage 2 mg daily and 1 mg of norethisterone acetate daily during one year period."( [Effect of Kliogest therapy on serum blood lipids in postmenopausal women].
Dydowicz, M; Hadaś, K; Halerz-Nowakowska, B; Korcz-Maciejewska, M; Meczekalski, B; Warenik-Szymankiewicz, A; Wiza, M, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (38.89)18.7374
1990's17 (31.48)18.2507
2000's15 (27.78)29.6817
2010's1 (1.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.62 (24.57)
Research Supply Index4.52 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index108.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (62.50%)5.53%
Reviews2 (3.57%)6.00%
Case Studies2 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other17 (30.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Clinical Trial on the Effectts of Estradiol 2 mg + NETA 1 mg With or Without Clodronate on Bone Mineral Density and Bone Markers of Osteoporotic Postmenopausal 167 Finnish Women. [NCT00877097]167 participants (Actual)Interventional1996-07-31Completed
Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol [NCT02638922]304 participants (Actual)Observational2014-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]